Sector: Health Care
Director information for INCYTE CORP (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Edmund P. Harrigan | Chair | [] | ["Audit and Finance Committee","Science and Technology Committee"] | 2026 | |
| Edmund P. Harrigan, M.D. | Independent Director | 73 | ["Senior Vice President of Worldwide Safety and Regulatory for Pfizer Inc.","Senior Vice President, Head of Worldwide Business Development at Pfizer","Senior Vice President, Head of Worldwide Regulatory Affairs and Quality Assurance at Pfizer","Vice President, Head of Neuroscience and Ophthalmology at Pfizer","Senior leadership positions at Karuna Pharmaceuticals, Inc., Sepracor Inc., and Neurogen Corporation","Practicing neurologist for seven years","Significant executive leadership experience in the pharmaceutical and biotechnology industry","Experience in drug discovery and development, regulatory affairs and business development","Substantial medical and scientific experience","Experience serving as a director of other publicly held life sciences companies"] | ["Science and Technology","Audit and Finance"] | 2026 |
| Jacqualyn A. Fouse | ["Qualified as an Audit Committee Financial Expert"] | ["Audit and Finance Committee","Nominating and Corporate Governance Committee"] | 2026 | ||
| Jacqualyn A. Fouse, Ph.D. | Independent Director | 64 | ["Chief Executive Officer of Agios Pharmaceuticals, Inc. from February 2019 until August 2022","Chair of the Agios Board of Directors since August 2022","Executive Chair of Dermavant Sciences from July 2017 to September 2018","Various roles at Celgene Corporation from September 2010 to June 2017","Chief Financial Officer of Bunge Limited from July 2007 to September 2010","Senior Vice President, Chief Financial Officer and Corporate Strategy at Alcon Laboratories, Inc.","Senior leadership roles with international companies in Europe including Swissair and Nestle","Significant executive leadership and corporate finance expertise"] | ["Audit and Finance","Nominating and Corporate Governance"] | 2026 |
| Jean-Jacques Bienaimé | Independent Director | 72 | ["Chief Executive Officer from May 2005 to November 2023 of BioMarin Pharmaceutical Inc.","Chair of the board of directors from June 2015 to November 2023 of BioMarin Pharmaceutical Inc.","Chair, Chief Executive Officer and President of Genencor","Chair, President and Chief Executive Officer of SangStat Medical Corporation","Various management positions at Rhône Poulenc Rorer Pharmaceuticals"] | ["Compensation (Chair)","Nominating and Corporate Governance","Nominating and Corporate Governance Committee"] | 2026 |
| Julian C. Baker | Chair of the Board | 59 | ["Managing Member of Baker Bros. Advisors LP","experienced investor in life sciences companies","significant strategic and financial expertise","extensive knowledge of the life sciences and biopharmaceuticals industries"] | ["Nominating and Corporate Governance","Compensation","Nominating and Corporate Governance Committee"] | 2026 |
| Katherine A. High | [] | ["Science and Technology Committee"] | 2026 | ||
| Katherine A. High, M.D. | Independent Director | 74 | ["Chief Executive Officer of RhyGaze AG","Former President, Therapeutics of Asklepios Biopharmaceutical, Inc.","Former President of Spark Therapeutics, Inc.","Former Head of Research and Development of Spark","Former Chief Scientific Officer of Spark","Professor at the Perelman School of Medicine at the University of Pennsylvania","Investigator of the Howard Hughes Medical Institute","Director of the Center for Cellular and Molecular Therapeutics at Children’s Hospital of Philadelphia","Visiting Professor at Rockefeller University"] | ["Science and Technology"] | 2026 |
| Otis W. Brawley | [] | ["Science and Technology Committee"] | 2026 | ||
| Otis W. Brawley, M.D. | Independent Director | 66 | ["Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University since January 2019","Chief Medical and Scientific Officer of the American Cancer Society from April 2007 to December 2018","Director of the Georgia Cancer Center at Grady Memorial Hospital from January 2002 to August 2007","Professor of hematology, oncology, medicine and epidemiology at Emory University from April 2001 to December 2018","Assistant director and senior investigator at the National Cancer Institute","Internist and oncologist at the National Institutes of Health Clinical Center and Bethesda Naval Hospital","Experience serving as a director of other publicly held life sciences companies"] | ["Science and Technology"] | 2026 |
| Paul J. Clancy | Independent Director; Chair | 64 | ["More than 30 years of experience in financial management and strategic business planning","Senior advisor to Alexion Pharmaceuticals, Inc.","Executive Vice President and Chief Financial Officer of Alexion Pharmaceuticals, Inc.","Executive Vice President, Finance and Chief Financial Officer of Biogen Inc.","Senior Vice President of Finance of Biogen","Vice President of Portfolio Management of Biogen","Joined Biogen in 2001 as Vice President of U.S. Marketing","13 years at PepsiCo Inc.","Qualified as an Audit Committee Financial Expert"] | ["Audit and Finance","Compensation","Audit and Finance Committee"] | 2026 |
| Susanne Schaffert | [] | ["Science and Technology Committee"] | 2026 | ||
| William J. Meury | Chief Executive Officer | 58 | ["Significant leadership and senior management experience","Experience in launching and commercializing healthcare products","Strong knowledge of strategy, markets, competitors, financials and operations"] | [] | 2026 |
